ScreenerHero

OCUL Ocular Therapeutix, Inc.

NAS · US · Healthcare · Biotechnology · ocutx.com
7.230USD-1.50%Mkt Cap: 1.59B $P/E: —

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation techno…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.59B USD
Enterprise Value1.09B USD
Revenue (TTM)52.05M USD
Gross Profit45.38M USD
Net Income (TTM)-265.94M USD
Revenue/Share0.24 USD
Last Price7.230 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees325
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.05
PEG—
EV/EBITDA-3.54
EV/Revenue20.99
P/S30.97
P/B3.10
EPS (TTM)-1.42
EPS (Forward)-1.45
52W Range
6.23010% of range16.44
52W High16.44 USD
52W Low6.230 USD
Profitability
Gross Margin87.35%
Oper. Margin-609.34%
EBITDA Margin0.00%
Profit Margin-511.90%
ROE-40.64%
ROA-32.91%
Growth
Revenue Growth0.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-204.88M USD
CapEx (TTM)12.01M USD
FCF Margin-305.92%
FCF Yield-10.03%
Net Debt-519.26M USD
Net Debt/EBITDA1.68
Balance Sheet
Debt/Equity0.12
Current Ratio13.11
Quick Ratio12.79
Book Value/Sh2.37 USD
Cash/Share2.73 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.09 USD
Upside (mean)+274.7%
Target Range18.00 USD – 34.00 USD
18.00+274.7% to mean34.00
# Analysts11
Ownership
Shares Out.219.62M
Float184.76M
Insiders0.93%
Institutions95.30%
Short Interest
Short Ratio11.1d
Short % Float16.09%
Short % Out.13.63%
Shares Short29.93M
Short (prev mo.)28.52M
Technical
SMA 509.736 (-25.7%)
SMA 2009.591 (-24.6%)
Beta0.99
S&P 52W Chg16.45%
Avg Vol (30d)3.49M
Avg Vol (10d)4.84M
Technical Indicators
RSI (14)31.6
MACD-0.8014
MACD Signal-0.5138
MACD Hist.-0.2875
BB Upper12.44 USD
BB Middle9.236 USD
BB Lower6.033 USD
BB Width69.35%
ATR (14)0.5967 USD
Vol Ratio (20d)0.79x